274 related articles for article (PubMed ID: 36619226)
1. A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes.
Damanhouri ZA; Alkreathy HM; Alharbi FA; Abualhamail H; Ahmad MS
Int J Med Sci; 2023; 20(1):142-150. PubMed ID: 36619226
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of oral antidiabetic therapy.
Ordelheide AM; Hrabě de Angelis M; Häring HU; Staiger H
Pharmacogenomics; 2018 Apr; 19(6):577-587. PubMed ID: 29580198
[TBL] [Abstract][Full Text] [Related]
3. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
Zolk O
Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
Nasykhova YA; Tonyan ZN; Mikhailova AA; Danilova MM; Glotov AS
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961860
[TBL] [Abstract][Full Text] [Related]
5. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic variation and metformin response.
Chen S; Zhou J; Xi M; Jia Y; Wong Y; Zhao J; Ding L; Zhang J; Wen A
Curr Drug Metab; 2013 Dec; 14(10):1070-82. PubMed ID: 24329113
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of Antidiabetic Drugs.
Srinivasan S; Yee SW; Giacomini KM
Adv Pharmacol; 2018; 83():361-389. PubMed ID: 29801583
[TBL] [Abstract][Full Text] [Related]
8. Metformin pharmacogenomics: current status and future directions.
Pawlyk AC; Giacomini KM; McKeon C; Shuldiner AR; Florez JC
Diabetes; 2014 Aug; 63(8):2590-9. PubMed ID: 25060887
[TBL] [Abstract][Full Text] [Related]
9. An update on the pharmacogenomics of metformin: progress, problems and potential.
Todd JN; Florez JC
Pharmacogenomics; 2014 Mar; 15(4):529-39. PubMed ID: 24624919
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic impact of SLC22A1 gene variant rs628031 (G/A) in newly diagnosed Indian type 2 diabetes patients undergoing metformin monotherapy.
Singh S; Shukla AK; Usman K; Banerjee M
Pharmacogenet Genomics; 2023 Apr; 33(3):51-58. PubMed ID: 36853844
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778
[TBL] [Abstract][Full Text] [Related]
13. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?
Chan P; Shao L; Tomlinson B; Zhang Y; Liu ZM
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1149-1159. PubMed ID: 30375241
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.
Staiger H; Schaeffeler E; Schwab M; Häring HU
Rev Diabet Stud; 2015; 12(3-4):363-76. PubMed ID: 27111121
[TBL] [Abstract][Full Text] [Related]
15. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
[TBL] [Abstract][Full Text] [Related]
16. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
[TBL] [Abstract][Full Text] [Related]
17. The pharmacogenetics of type 2 diabetes: a systematic review.
Maruthur NM; Gribble MO; Bennett WL; Bolen S; Wilson LM; Balakrishnan P; Sahu A; Bass E; Kao WH; Clark JM
Diabetes Care; 2014; 37(3):876-86. PubMed ID: 24558078
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy for type 2 diabetes: dapagliflozin plus metformin.
Tan X; Hu J
Expert Opin Pharmacother; 2016; 17(1):117-26. PubMed ID: 26567559
[TBL] [Abstract][Full Text] [Related]
19. Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort.
Wancewicz B; Zhu Y; Fenske RJ; Weeks AM; Wenger K; Pabich S; Daniels M; Punt M; Nall R; Peter DC; Brasier A; Cox ED; Davis DB; Ge Y; Kimple ME
J Pharmacol Exp Ther; 2023 Aug; 386(2):169-180. PubMed ID: 36918276
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine: The future in diabetes care?
Scheen AJ
Diabetes Res Clin Pract; 2016 Jul; 117():12-21. PubMed ID: 27329017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
